The Responsible Person in the EU
Only cosmetic products for which a Responsible Person is designated in the European Union can be placed on the EU market. The Responsible Person must ensure full compliance with the European Cosmetic Regulation.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


According to the European Regulation on Cosmetic Products (Regulation (EC) No 1223/2009, Article 4), only cosmetic products for which a legal or natural person is designated as a “Responsible Person” can be placed on the EU market. So, the Responsible Person (RP) is an entity established in one of the Member States of the EU.

The manufacturer of domestic products (company who manufacturers or orders the manufacturing under their name) is by default the RP. On the other hand, when a cosmetic product is imported (i.e., manufactured outside the EU), each importer is by default the RP for the specific product he places on the market. However, the manufacturer or importer may contractually appoint a third party to become the RP, who must accept it in writing (written mandate).

When a distributor places a cosmetic product on the market under his name or trademark or modifies a product beyond label translation, he becomes the RP of the such product.


The RP is fully responsible for safety and legal compliance.

Before placing a cosmetic product on the EU market, the RP must ensure that it has undergone a safety assessment and that the cosmetic product is considered safe for human health when used under normal and reasonable foreseeable conditions of use.

The electronic notification of the cosmetic product in the Cosmetic Product Notification Portal (CPNP), before making the product available on the market, shall be made by the RP. (see previous post)

The RP needs to keep a Product Information File (PIF) and make it readily accessible to the competent authority of the Member State in which the file is kept.

This entity must be clearly identified (name and address) to authorities and consumers through product notification and labelling. This means that the name (or registered name) and the address of the Responsible Person must be indicated in the label of the cosmetic product. Products without and identified RP will be stopped at customs or withdrawn from the market.

Post-market surveillance, such as reporting serious undesirable effects to the competent authority, is also a responsibility of the RP.

Some other obligations of the RP are related to: restrictions for substances; animal testing requirements; product claims; labelling requirements; and others.

In sum, each cosmetic product placed in the EU market must have a Responsible Person, who shall ensure full compliance with Regulation (EC) No 1223/2009 on cosmetic products.

If you need any information regarding this or other subjects, fell free to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »